News

The marketing denial orders were due to what the FDA stated as insufficient data supporting the products' additional benefit for adults switching from smoking cigarettes to vaping or cessation.

The findings from these 2 trials for bimekizumab may lead to greater treatment options for patients with HS, an often debilitating and chronic skin condition.

An update from Apellis reports 10 confirmed events of retinal vasculitis and 2 suspected events associated with pegcetacoplan injection for geographic atrophy.

Biosimilars to several recognized biologic rheumatoid arthritis treatments are now approved for use in the United States. Test your knowledge with this quiz.

In a 12-month, real-world study, the implant was effective in more than half of eyes with non-infectious uveitis, achieving effectiveness as soon as 2 weeks post-implantation.

The new data on this drug’s effects on maintenance of clinical response indicates the strength of the treatment for individuals with the immune-mediated skin disease.

More than half of patients in the mirikizumab arm achieved clinical remission at week 52.

Findings showed the probability of achieving total remission was significantly greater in the corticosteroid pulse group compared to the oral corticosteroid group.

A group of 9 experts in heart failure, ranging from leading trialists to early career clinicians, provide perspective on what they see as the biggest news in heart failure from 2023.

The new results from 3 different phase 3 studies presented at EADV on nemolizumab for those with prurigo nodularis and eczema show promise for the treatment.

Ahmad Masri, MD, MS, discusses long-term data from the open-label extension period of the phase 2 AG10-201 trial examining acoramidis in patients with ATTR-CM.

This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.

Age, fecal calprotectin level, toxin B PCR cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent CDI.

On October 10, 2023, Novo Nordisk announced they would be stopping the FLOW trial, which examined the effects of semaglutide 1.0 mg on kidney outcomes in type 2 diabetes, due to early efficacy based on an interim analysis of the trial.

Fibrosis regression was prevalent among 57% of the cohort and was associated with older age and advanced fibrosis at baseline.

This new data on the negative impacts of skin disease on individuals in 27 countries in Europe demonstrates the lasting impacts of stigmatization.

Faricimab maintained vision improvements and extended treatment intervals up to 4 months for people with RVO in the phase 3 BALATON and COMINO trials.

Ahmad Masri, MD, MS, offers perspective om the study design of the ACACIA-HCM trial and the unmet need within nonobstructive hypertrophic cardiomyopathy.

This new recommendation by the European Academy of Allergy and Clinical Immunology was put forward to help guide clinical practices.

In a recent case series, a substantial percentage of patients with GA experienced "floaters" from presumed intravitreal silicone oil droplets after pegcetacoplan injection.

Ankeet Bhatt, MD, MBA provides additional perspective on a recent study examining the cost-effectiveness and health impact of sacubitril/valsartan use at different thresholds of ejection fraction.

Use of antiviral therapy was linked to a decreased risk of multiple cardiovascular outcomes and mortality compared to patients not using antiviral therapy.

Social vulnerability index, race, and poverty were associated with increased rates of CDI, calling attention to population-level health disparities.

Ankeet Bhatt, MD, MBA, offers perspective into the results of a recent analysis of the GWTG-HF registry at HFSA 2023.

This new data represents the first real-world, US-based data on this drug, demonstrating the efficacy and the safety indications of these clinical trials.

Data from a phase 1b trial presented at HFSA 2023 detail the effects of JK07, an investigational agent from Salubris Biotherapeutics, in patients with heart failure with reduced ejection fraction.

On the floor at HFSA 2023, Muthiah Vaduganathan, MD, MPH, provides his perspective on the latest IV iron supplementation guidelines from the European Society of Cardiology.

This new data from 27 European countries resulted in several notable findings with regard to the journey of patients with skin disease in various healthcare environments.